Compare · Head-to-head
Hexarelin vs Sermorelin.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Sermorelin, then use the table to confirm fit.
Sermorelin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | Hexarelin | Sermorelin |
|---|---|---|
| Primary fit | muscle growth & strength and sleep & relaxation comparisons | gh axis optimization research where you want a clear starting point |
| Evidence | Tier B-C | Tier B |
| Risk | high | medium |
| Experience level | advanced | intermediate |
| Budget tier | mid | mid |
| Administration route | subcutaneous, intravenous | subcutaneous |
02 · Use case & timing
| Decision factor | Hexarelin | Sermorelin |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Sleep & Relaxation, GH Axis Optimization | GH Axis Optimization |
| What users compare it for | GH-axis modulation; sleep architecture research interest. | GH axis stimulation; growth/body composition changes over months. |
| Onset timeline | Acute endocrine effects; sleep effects studied overnight. | GH secretion changes occur acutely; body composition endpoints are months-horizon. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Hexarelin | Sermorelin |
|---|---|---|
| Adverse effects | Endocrine spillover (ACTH, cortisol, prolactin). | Glucose intolerance risk; theoretical neoplasia concerns with sustained IGF-1 elevation. |
| Contraindications | No formal label. | Active malignancy (by analogy to tesamorelin class warnings). |
| Interaction notes | Unknown; caution with other GH-axis compounds. | Unknown interaction profile outside supervised settings. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA status unclear |
| WADA status | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | Hexarelin | Sermorelin |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Hexarelin | Sermorelin |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $480.00 |
| Estimated monthly cost | No reliable estimate yet | $160.00 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | Hexarelin | Sermorelin |
|---|---|---|
| Tracked vendor listings | 0 listings | 1 listing |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.